When the FDA approved fezolinetant for treating moderate to severe hot flashes in menopausal women, the news made headlines. At last, a non-hormonal option that worked by targeting the brain’s ...

The U.S. Food and Drug Administration has extended its review of Bayer's experimental menopause relief drug, the German ...

The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and the U.K. have already cleared it for use.

“It’s going to reduce hot flashes, they say, in over 50% of women, reduce them by 50%. If those numbers are accurate, this is going to be a wonder drug.” ...

The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.

WASHINGTON — U.S. health regulators on Friday approved a new type of drug for women dealing with uncomfortable hot flashes caused by menopause. The Food and Drug Administration approved the once ...